Non-relapse mortality and decision curve analysis of patients stratified by clinical models alone or in combination with biomarkers. Six-month NRM for (A) MAGIC patients classified to be HSL–high risk (patients with liver involvement or patients ≥50 years old who also had grade 3-4 acute GVHD) vs HSL–low risk (all other combinations); (B) patients in the HSL–high-risk subgroup classified based on high vs low MAP; (C) patients in the HSL–low-risk subgroup classified based on high vs low MAP; (D) patients classified based on the combination of the HSL model and the MAP (blue, HSL–low-risk and low MAP; purple, HSL–low-risk and high MAP or HSL–high-risk and low MAP; and red, HSL–high-risk and high MAP); (E) patients classified based on the combination of the Minnesota (Minn) risk system and the MAP (blue, Minn standard-risk and low MAP; purple, Minn standard-risk and high MAP or Minn high-risk and low MAP; and red, Minn high-risk and high MAP). (F) DCA for the HSL clinical model (orange) and the combined HSL clinical and MAP (as a continuous variable) model (green) for 6-month NRM.